Key statistics
As of last trade Urogen Pharma Ltd (0XOD:LSE) traded at 21.18, -28.88% below its 52-week high of 29.78, set on Nov 28, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 21.18 |
| Low | 21.18 |
| Bid | -- |
| Offer | -- |
| Previous close | 21.18 |
| Average volume | 348.86 |
|---|---|
| Shares outstanding | 46.81m |
| Free float | 44.99m |
| P/E (TTM) | -- |
| Market cap | 940.86m USD |
| EPS (TTM) | -3.31 USD |
Data delayed at least 20 minutes, as of Feb 13 2026 15:29 GMT.
More ▼
Announcements
- UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
- Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
- UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
- UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
- UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
- UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
- Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
- ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
More ▼
